Pelthos Therapeutics Inc.
PTHSFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Pelthos Therapeutics Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 4 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 17, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Pelthos Therapeutics Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-11-25 · Friedberg Ezra M: Larger than all 14 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-15 | Friedberg Ezra M · Director | Common Stock | S — Open market or private sale | −59 | 27.94 | SEC filing |
| 2026-06-15 | Friedberg Ezra M · Director | Common Stock | S — Open market or private sale | −224 | 27.12 | SEC filing |
| 2026-06-11 | Davis Todd C · Director | Common Stock | P — Open market or private purchase | +35,445 | 27.80 | SEC filing |
| 2026-06-11 | Davis Todd C · Director | Common Stock | P — Open market or private purchase | +503 | 28.73 | SEC filing |
| 2026-05-22 | Francis Knuettel II · CFO, Treas & Secty | Common Stock | S — Open market or private sale | −1,500 | 26.84 | SEC filing |
| 2026-04-02 | Pauls Matthew · Director | Common Stock | S — Open market or private sale | −371 | 21.36 | SEC filing |
| 2026-04-02 | Friedberg Ezra M · Director | Common Stock | S — Open market or private sale | −265 | 21.36 | SEC filing |
| 2026-04-02 | Greenleaf Peter · Director | Common Stock | S — Open market or private sale | −377 | 21.36 | SEC filing |
Showing 8 of 19 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-22 | Francis Knuettel II · CFO, Treas & Secty | Stock Option | A — Grant, award, or other acquisition | +59,500 | SEC filing |
| 2026-05-14 | Friedberg Ezra M · Director | Common Stock | F — Payment of exercise price or tax by delivering securities | −144 | SEC filing |
| 2025-12-23 | Einhorn Andrew J. · Director | Common Stock | A — Grant, award, or other acquisition | +12,000 | SEC filing |
| 2025-12-17 | LIGAND PHARMACEUTICALS INC · Director, 10% owner | Senior Secured Convertible Note | A — Grant, award, or other acquisition | +unknown | SEC filing |
| 2025-12-10 | Pauls Matthew · Director | Common Stock | G — Bona fide gift | −9,542 | SEC filing |
| 2025-11-13 (amended) | Malamut Richard · Director | Common Stock | A — Grant, award, or other acquisition | +2,454 | SEC filing |
| 2025-11-06 | LIGAND PHARMACEUTICALS INC · Director, 10% owner | Senior Secured Convertible Note | A — Grant, award, or other acquisition | +unknown | SEC filing |
| 2025-10-02 | Pauls Matthew · Director | Restricted Stock Units | M — Exercise or conversion of derivative security | −2,123 | SEC filing |
Showing 8 of 24 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-22 | Francis Knuettel II · CFO, Treas & Secty | Common Stock | D — Disposition to the issuer | −13,947 | SEC filing |
| 2026-05-22 | Francis Knuettel II · CFO, Treas & Secty | Stock Option | D — Disposition to the issuer | −42,500 | SEC filing |
| 2025-12-17 | LIGAND PHARMACEUTICALS INC · Director, 10% owner | Senior Secured Convertible Note | D — Disposition to the issuer | −unknown | SEC filing |
| 2025-07-01 | Davis Todd C · Director, 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +31,279 | SEC filing |
| 2025-07-01 | Francis Knuettel II · Chief Financial Officer | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +10,000 | SEC filing |
| 2025-07-01 | LIGAND PHARMACEUTICALS INC · 10% owner | Series A Convertible Preferred Stock | J — Other acquisition or disposition | +31,279 | SEC filing |
Showing 6 of 6 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.